

FOR IMMEDIATE RELEASE

MassBiologics announces partnership with SparingVision to manufacture gene therapy for ocular disease

Sept. 18, 2023 – [MassBiologics of UMass Chan Medical School](#) has entered into a partnership with France-based [SparingVision](#), a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases.

MassBiologics will provide dedicated manufacturing and process development teams at its South Coast facility, which specializes in the manufacturing of viral vectors, a delivery system by which genetic material can be delivered to cells to treat diseases.

“We are delighted to collaborate with SparingVision to create new medicines for rare diseases,” said Diana Morales, deputy director of business development at MassBiologics. “For more than 125 years, MassBiologics has researched, developed, manufactured and distributed medicines to improve lives. Our technical expertise and teams are ready to help our client through the commercialization process.”

MassBiologics will manufacture Sparing Visions’ investigational adeno-associated virus gene therapy product, SPVN20, to restore visual acuity and color vision in patients with late-stage retinitis pigmentosa and other inherited retinal diseases.

###

About MassBiologics: MassBiologics is a CDMO with demonstrated experience in clinical and commercial manufacturing of gene therapy products. MassBiologics of UMass Chan Medical School is the only nonprofit, FDA-licensed manufacturer of vaccines, biologics and viral vector gene therapies in the United States.

For media, please contact:

Sarah Willey
Media Relations Manager
UMass Chan Medical School
Cell: 774-284-0186
Email: sarah.willey@umassmed.edu